Finance

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

SHANGHAI,Feb. 23,2025-- BioCityBiopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist,SC0062,met the 12-week primary endpoint of a reduction in proteinuria in the

Finance

Feb 26, 2025

How 51Talk is Redefining Online Education Through AI--from the Boardroom to the Classroom

SINGAPORE,Feb. 25,2025--51Talk,an online English language education platform,has announced plans to launch a comprehensive,AI-powered systems upgrade across its business operations within the coming m

Finance

Feb 26, 2025

China committed to acting as an 'enabler'

BEIJING,Feb. 25,2025-- A report from People\'s Daily: Recently,a foreign scholar described China as an "enabler." This term vividly encapsulates China\'s commitment to building a community w

Finance

Feb 26, 2025

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

SHANGHAI,Feb. 25,2025-- WuXi XDC Cayman Inc. ("WuXi XDC",or the "Company",stock code: 2268.HK),a leading global CRDMO (Contract Research,Development,and Manufacturing Organization)

Finance

Feb 26, 2025

Axiad Applauded by Frost & Sullivan for Providing Phishing-resistant Authentication with PKI-based Authentication

Axiad\'s PKI-based authentication enables scalability and flexibility in large-scale enterprise environments,elevates user experience and streamlines user access control

Finance

Feb 26, 2025

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

SHANGHAI,Feb. 25,2025-- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK,"CARsgen Therapeutics"),a company focused on innovative CAR T-cell therapies for the treatment of hematolo

Finance

Feb 26, 2025

1 ... 56 57 58 59 60 61 62 ... 113